|
|
|
|
|
|
Europe is becoming less attractive for pharmaceutical innovation after two decades of declining R&D investment, says pharma industry leader. Europe needs a much more coordinated discussion on how it values medicines and innovation if it wants to withstand mounting geopolitical and trade pressures, argues Nathalie Moll, director general of the European Federation of Pharmaceutical Industries and Associations.
|
|||||
|
|
27 February 2026
Impact of Innovative Medicines/Health Initatives projects on rare diseases
Rare diseases present unique scientific, clinical and economic challenges, and through IMI and IHI public-private partnerships,...
|
||
|
|
22 April 2026
The €240 billion leak: Why Europe’s health resilience starts with integrated obesity, diabetes...
Europe is treating the symptoms of a crisis while ignoring the drivers behind it. By the time an EU citizen is diagnosed...
|
||
|
|
|
|||||||||
|
|
Europe’s Choice: Investing in sustainable health systems
Brussels, Belgium
At a time when health budgets are strained, public finances are under pressure, the health workforce crisis is deepening,... Learn more → |
|||
|
Towards comprehensive cardiovascular health checks across Europe
Brussels, Belgium
Cardiovascular disease (CVD) remains the leading cause of mortality and morbidity in Europe, despite significant advances... Learn more → |
|||
|
|
An EU Action Plan on Rare Diseases would offer a coherent framework for improving the lives of millions of people. For the 30 million people in Europe living with rare diseases, limited access to diagnosis and care has a profound impact on quality of life. For many conditions, the lack of treatment options is a major barrier to achieving better health outcomes. Addressing policy fragmentation and overcoming hurdles to research and development could unlock much-needed progress.
|
|
| Swedish rare disease patients endure longer wait for new medicines 09 June 2026 (Euractiv) | Read more → |
| It takes more than 21 months for a new orphan drug to reach Sweden, the average time to availability... 09 June 2026 (Euractiv) | Read more → |
|
|||
|
||||
|
EFPIA 2026 All rights reserved ·
Disclaimer
·
|